Atogepant for Prevention of Episodic Migraine-- Primary Outcome Measure Met in Phase 2b/3 Clinical Trial 

  • Atogepant
  • Headache
  • Migraine
  • Pain

Results of a phase 2b/3 clinical trial (NCT02848326) show that atogepant (Allergan, Madison, NJ) treatment significantly reduced the mean number of migraine days over a 12-week period for people with migraine, meeting the trial’s primary efficacy endpoint (Table). 

Atogepant was well tolerated and no treatment-related serious adverse events occurred.  Reductions in monthly migraine days were seen as early as weeks 1-4 and were sustained over 12 weeks of treatment. Atogepant is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist that is orally available.

In exploratory analysis of the data from this trial, the proportion of patients achieving different response rates (25%, 50%, 75%, and 100%) were compared to the proportion of participants with that response rate from placebo. Treatment with any of the 5 doses of atogepant vs placebo resulted in a significantly larger proportion of participants achieving the response rate measured (25% response: 71%-84% vs 63%, 50% response: 52%-62% vs 40%, 75% response 29%-37% vs 18%, and 100% response: 7%-11% vs 3%). 

These results were presented at the American Headache Society’s 61st Annual Meeting July 11-14 in Philadelphia PA. 

In a late-breaking presentation at the meeting, it was shown that in animal models extracranial injections of onabotulinumtoxinA (Botox; Allergan, Madison, NJ) in combination with intravenous injection of atogepant attenuates activation and sensitization of c-fiber, high-threshold (TH) and A-delta, wide dynamic range (WDR) pathways.  These findings suggest that a combination therapy that blocks both these pathways may be more effective than a monotherapy that blocks only one of them.

Phase 2 Trial of Niflamapimod for Dementia With Lewy Bodies Begins

Previous News Article

Healthy Lifestyle Choices May Decrease Dementia Risk Even for People With Genetic Predispositions to Alzheimer’s Disease

Next News Article
This Month's Issue
Pompe Disease

Jonathan Cauchi, MD

The Future of Neuromuscular Disorders is Now

Monika Krzesniak-Swinarska, MD

Symptoms of Lewy Body Dementia Induced by Herpes Zoster Encephalitis

Ryan Verity, MD; Andrew Kirk, MD, FRCPC; and Gary Hunter, MD, FRCPC, CSCN(EEG)